within Pharmacolibrary.Drugs.ATC.C;

model C07AB13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 2.2,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007666666666666667,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Talinolol is a selective beta-1 adrenergic receptor blocker primarily used as an antihypertensive agent for the treatment of high blood pressure and certain types of cardiac arrhythmias. It is not widely used today as other beta-blockers are more commonly prescribed. Talinolol is approved in some countries but not universally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, both male and female, in oral dosing studies.</p><h4>References</h4><ol><li><p>Han, Y, et al., &amp; Zhou, HH (2009). Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 39(9) 694–699. DOI:<a href=&quot;https://doi.org/10.1080/00498250903060077&quot;>10.1080/00498250903060077</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19555315/&quot;>https://pubmed.ncbi.nlm.nih.gov/19555315</a></p></li><li><p>Krueger, M, et al., &amp; Preiss, R (2001). Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers. <i>International journal of clinical pharmacology and therapeutics</i> 39(2) 61–66. DOI:<a href=&quot;https://doi.org/10.5414/cpp39061&quot;>10.5414/cpp39061</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11270803/&quot;>https://pubmed.ncbi.nlm.nih.gov/11270803</a></p></li><li><p>He, X, et al., &amp; Ouyang, DS (2012). Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 42(12) 1248–1254. DOI:<a href=&quot;https://doi.org/10.3109/00498254.2012.697590&quot;>10.3109/00498254.2012.697590</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22725663/&quot;>https://pubmed.ncbi.nlm.nih.gov/22725663</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C07AB13;
